Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 6/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.49 |
| ▸ | CA12 | O43570 | 4/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2441516 | 0.82 | TAAR1 (0.50) | RECQLTAAR1CA2CA1CA12 | |
| SCHEMBL6608518 | 0.80 | RECQL (0.67) | RECQLCA2CA1CA12CA4 | |
| SCHEMBL27825383 | 0.80 | TAAR1 (0.48) | RECQLTAAR1CA2CA1CA12 | |
| SCHEMBL11166463 | 0.80 | RECQL (0.96) | RECQLCA2CA1CA12CA4 | |
| SCHEMBL29001390 | 0.80 | MGLL (0.48) | RECQLTAAR1CA2CA1CA12 | |
| SCHEMBL8113789 | 0.78 | RECQL (0.64) | RECQLTAAR1CA2CA1CA12 | |
| SCHEMBL66512 | 0.78 | APLNR (0.50) | RECQLTAAR1CA2CA1CA12 | |
| SCHEMBL20495284 | 0.78 | PTGS2 (0.47) | RECQLTAAR1CA2CA1CA12 | |
| SCHEMBL5725397 | 0.78 | RECQL (0.64) | RECQLCA2CA1CA12CA4 | |
| SCHEMBL29046728 | 0.78 | RECQL (0.64) | RECQLTAAR1CA2CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101993416-A | Quinoline compound and preparation method thereof, medicament combination containing compound and application of compound | SHANGHAI INST MATERIA MEDICA | 2011-03-30 | — | — | CN | claimed |
| US-20250326713-A1 | INHIBITORS OF MsbA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250312362-A1 | INHIBITORS OF MsbA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4525851-A1 | INHIBITORS OF MSBA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525852-A1 | INHIBITORS OF MSBA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023224892-A1 | INHIBITORS OF MSBA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023224893-A1 | INHIBITORS OF MSBA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-101993416-B | Quinoline compound and preparation method thereof, medicament combination containing compound and application of compound | SHANGHAI INST MATERIA MEDICA | 2013-09-11 | — | — | CN | disclosed |
| CN-101993416-A | Quinoline compound and preparation method thereof, medicament combination containing compound and application of compound | SHANGHAI INST MATERIA MEDICA | 2011-03-30 | — | — | CN | disclosed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| CN-101263133-A | New pyridine analogues | ASTRAZENECA AB (SE) | 2008-09-10 | — | — | CN | disclosed |
| EP-1940835-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-07-09 | — | — | EP | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007036733-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| EP-1191026-B1 | New pyridazine endothelin antagonists | PFIZER LTD (GB) | 2004-05-19 | — | — | EP | disclosed |
| US-6670362-B2 | Treatment of restenosis, acute or chronic renal failure, pulmonary hypertension, systemic hypertension, benign prostatic hyperplasia, male erectile dysfunction, prostate cancer, metastatic bone cancer, angina, atherosclerosis | PFIZER INC. | 2003-12-30 | — | — | US | disclosed |
| US-20020061889-A1 | New pyridazine endothelin antagonists | PFIZER INC. | 2002-05-23 | — | — | US | disclosed |
| EP-1191026-A1 | New pyridazine endothelin antagonists | Pfizer Limited (GB) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312362-A1 | INHIBITORS OF MsbA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MSRB3, ABCC1, MRPS34 | RECQL 168/4885TAAR1 4586/4885CA2 2766/4885 |
| US-20020061889-A1 | New pyridazine endothelin antagonists | EDNRB, EDNRA, ECE1 | RECQL 2541/4885TAAR1 61/4885CA2 3254/4885 |
| US-20250326713-A1 | INHIBITORS OF MsbA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MSRB3, ARSA, ABCG2 | RECQL 242/4885TAAR1 3599/4885CA2 2632/4885 |
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | RECQL 555/4885TAAR1 1568/4885CA2 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.